Experienced in Childhood Acute Myeloid Leukemia

Dr. Nehal Masood

Hematology Oncology | Hematology | Oncology
317 Martin Luther King Jr Way, 
Tacoma, WA 
Accepting New Patients
Offers Telehealth
Experienced in Childhood Acute Myeloid Leukemia
317 Martin Luther King Jr Way, 
Tacoma, WA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Nehal Masood is a Hematologist Oncology specialist and a Hematologist in Tacoma, Washington. Dr. Masood and is rated as an Experienced provider by MediFind in the treatment of Childhood Acute Myeloid Leukemia. His top areas of expertise are Lung Cancer, Pleuropulmonary Blastoma, Small Cell Lung Cancer (SCLC), and Angiosarcoma. Dr. Masood is currently accepting new patients.

His clinical research consists of co-authoring 22 peer reviewed articles and participating in 5 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology Oncology
Hematology
Oncology
Licenses
Internal Medicine in KY
Hospital Affiliations
Multicare Auburn Medical Center
Capital Medical Center
Tacoma General Allenmore Hospital
Multicare Good Samaritan Hospital
Languages Spoken
English
Castilian
Hindi
Mandarin
Spanish
Swedish
Tamil
Urdu
Vietnamese
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
PacificSource
  • PPO
Premera
  • EPO
  • PPO

Locations

MULTICARE HEALTH SYSTEM
317 Martin Luther King Jr Way, Tacoma, WA 98405
Other Locations
MULTICARE HEALTH SYSTEM
1901 S Union Ave, Tacoma, WA 98405

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

A Phase 1b Study to Evaluate the Safety and Clinical Activity of AB122 in Biomarker-Selected Participants With Advanced Solid Tumors
A Phase 1b Study to Evaluate the Safety and Clinical Activity of AB122 in Biomarker-Selected Participants With Advanced Solid Tumors
Enrollment Status: Completed
Publish Date: September 19, 2024
Intervention Type: Drug
Study Phase: Phase 1
A Phase 1/1b Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Breast or Gynecologic Malignancies
A Phase 1/1b Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Breast or Gynecologic Malignancies
Enrollment Status: Completed
Publish Date: May 24, 2024
Intervention Type: Drug
Study Drugs: Etrumadenant, IPI-549, Pegylated liposomal doxorubicin, Nab-paclitaxel
Study Phase: Phase 1
A Phase III Randomized, Controlled, Open-label, Multicenter, Global Study of Capmatinib in Combination With Osimertinib Versus Platinum - Pemetrexed Based Doublet Chemotherapy in Patients With Locally Advanced or Metastatic NSCLC Harboring EGFR Activating Mutations Who Have Progressed on Prior Generation EGFR-TKI Therapy and Whose Tumors Are T790M Mutation Negative and Harbor MET Amplification (GEOMETRY-E)
A Phase III Randomized, Controlled, Open-label, Multicenter, Global Study of Capmatinib in Combination With Osimertinib Versus Platinum - Pemetrexed Based Doublet Chemotherapy in Patients With Locally Advanced or Metastatic NSCLC Harboring EGFR Activating Mutations Who Have Progressed on Prior Generation EGFR-TKI Therapy and Whose Tumors Are T790M Mutation Negative and Harbor MET Amplification (GEOMETRY-E)
Enrollment Status: Terminated
Publish Date: March 05, 2024
Intervention Type: Drug
Study Drugs: Capmatinib, Pemetrexed, Cisplatin, Carboplatin, Osimertinib
Study Phase: Phase 3
A Randomized Phase 2 Trial of AM0010 in Combination With Pembrolizumab vs. Pembrolizumab Alone as First-Line (1L) Therapy in Patients With Stage IV / Metastatic Wild Type (WT) Non-Small Cell Lung Cancer and Tumors With High Expression of PD-L1 (> 50%)
A Randomized Phase 2 Trial of AM0010 in Combination With Pembrolizumab vs. Pembrolizumab Alone as First-Line (1L) Therapy in Patients With Stage IV / Metastatic Wild Type (WT) Non-Small Cell Lung Cancer and Tumors With High Expression of PD-L1 (> 50%)
Enrollment Status: Terminated
Publish Date: January 20, 2021
Intervention Type: Drug, Biological
Study Phase: Phase 2
A Randomized Phase 2 Trial of AM0010 in Combination With Nivolumab vs. Nivolumab Alone as Second-Line Therapy in Subjects With Stage IV / Metastatic Wild Type Non-Small Cell Lung Cancer and Low Tumor Expression of PD-L1
A Randomized Phase 2 Trial of AM0010 in Combination With Nivolumab vs. Nivolumab Alone as Second-Line Therapy in Subjects With Stage IV / Metastatic Wild Type Non-Small Cell Lung Cancer and Low Tumor Expression of PD-L1
Enrollment Status: Terminated
Publish Date: September 11, 2020
Intervention Type: Biological, Drug
Study Phase: Phase 2
View 4 Less Clinical Trials

22 Total Publications

Safety, Efficacy, and Pharmacokinetics of Almonertinib (HS-10296) in Pretreated Patients With EGFR-Mutated Advanced NSCLC: A Multicenter, Open-label, Phase 1 Trial.
Safety, Efficacy, and Pharmacokinetics of Almonertinib (HS-10296) in Pretreated Patients With EGFR-Mutated Advanced NSCLC: A Multicenter, Open-label, Phase 1 Trial.
Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
Published: May 18, 2020
Similar Doctors
Distinguished in Childhood Acute Myeloid Leukemia
Dr. Laura S. Connelly-Smith
Hematology | Oncology | Hematology Oncology
Distinguished in Childhood Acute Myeloid Leukemia
Dr. Laura S. Connelly-Smith
Hematology | Oncology | Hematology Oncology

The Association Of University Physicians

825 Eastlake Ave E, 
Seattle, WA 
 (26.1 mi)
206-288-1000
Languages Spoken:
English, Farsi, Portuguese, Russian, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Laura Connelly-Smith is a Hematologist and an Oncologist in Seattle, Washington. Dr. Connelly-Smith and is rated as a Distinguished provider by MediFind in the treatment of Childhood Acute Myeloid Leukemia. Her top areas of expertise are Chronic Myelogenous Leukemia (CML), Philadelphia-Negative Chronic Myeloid Leukemia, Childhood Acute Myeloid Leukemia, Acute Myeloblastic Leukemia without Maturation, and Bone Marrow Transplant. Dr. Connelly-Smith is currently accepting new patients.

Distinguished in Childhood Acute Myeloid Leukemia
Dr. Mary-elizabeth M. Percival
Hematology | Oncology | Hematology Oncology
Distinguished in Childhood Acute Myeloid Leukemia
Dr. Mary-elizabeth M. Percival
Hematology | Oncology | Hematology Oncology

The Association Of University Physicians

825 Eastlake Ave E, 
Seattle, WA 
 (26.1 mi)
206-288-1000
Languages Spoken:
English, Bengali, Korean, Spanish, Vietnamese
See accepted insurances
Accepting New Patients
Offers Telehealth

Mary-elizabeth Percival is a Hematologist and an Oncologist in Seattle, Washington. Dr. Percival and is rated as a Distinguished provider by MediFind in the treatment of Childhood Acute Myeloid Leukemia. Her top areas of expertise are Acute Myeloid Leukemia (AML), Leukemia, Myelodysplastic Syndrome (MDS), Bone Marrow Aspiration, and Bone Marrow Transplant. Dr. Percival is currently accepting new patients.

Distinguished in Childhood Acute Myeloid Leukemia
Dr. Vivian G. Oehler
Oncology | Hematology Oncology
Distinguished in Childhood Acute Myeloid Leukemia
Dr. Vivian G. Oehler
Oncology | Hematology Oncology

The Association Of University Physicians

1959 Ne Pacific St, 
Seattle, WA 
 (27.8 mi)
206-598-4333
Languages Spoken:
English, German, Spanish, Vietnamese
See accepted insurances
Accepting New Patients
Offers Telehealth

Vivian Oehler is an Oncologist and a Hematologist Oncology provider in Seattle, Washington. Dr. Oehler and is rated as a Distinguished provider by MediFind in the treatment of Childhood Acute Myeloid Leukemia. Her top areas of expertise are Chronic Myelogenous Leukemia (CML), Acute Myeloid Leukemia (AML), Leukemia, Philadelphia-Negative Chronic Myeloid Leukemia, and Bone Marrow Aspiration. Dr. Oehler is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Masood's expertise for a condition
ConditionClose
    View All 13 Distinguished Conditions
    View All 30 Advanced Conditions
    View All 123 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile